AI-Enhanced Optimization of Acute Levodopa Challenge Test
NCT ID: NCT06949865
Last Updated: 2025-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2024-05-28
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China
NCT03649503
Machine Vision Based MDS-UPDRS III Machine Rating
NCT05906719
A Pilot Study to Evaluate the Severity of Motor Dysfunction in Parkinson's Disease Based on AI Video Analysis
NCT03655171
7.0T Magnetic Resonance Imaging Study of Parkinson's Disease
NCT06449404
Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms
NCT04858893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinson's disease (PD) group:
Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Multiple system atrophy (MSA) group
Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Progressive supranuclear palsy (PSP) group
Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Vascular parkinsonism (VP) group
In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Drug-induced parkinsonism (DIP) group
Parkinsonism.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Corticobasal degeneration (CBD) group
Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Dementia with Lewy Bodies (DLB) Group
Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
video recording
The patient's motor symptoms were recorded via video for assessment purposes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
3. Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
4. Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
5. Drug-induced parkinsonism (DIP) group: 1. Parkinsonism; 2. Drug history, the appearance of symptoms is related to specific drugs; 3. Symptoms are reversible, and the symptoms are reduced or disappeared when the corresponding drugs are reduced; 4. Rule out other causes; 5. Subjects are 50-75 years old (including boundary values), gender is not limited; 6. Agree to undergo study-related examination evaluation and sign informed consent.
6. Corticobasal degeneration (CBD) group: 1. Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
7. Dementia with Lewy Bodies (DLB) Group: 1. Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria. 2. Exhibits symptoms of Parkinsonism. 3. Subjects are aged 50-75 years (inclusive), with no gender restriction. 4. Agree to undergo study-related assessments and evaluations and signs the informed consent form.
Exclusion Criteria
2. Inability to tolerate levodopa shock test
3. Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases
4. Those with serious behavioral problems or mental disorders
5. Inability to sign informed consent
6. Other conditions that are considered unsuitable by the investigator to participate in this study.
50 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Nanjing Medical University
OTHER
Second Affiliated Hospital of Soochow University
OTHER
Beijing Hospital
OTHER_GOV
Fujian Medical University Union Hospital
OTHER
Guangdong Provincial People's Hospital
OTHER
West China Hospital
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
China-Japan Union Hospital, Jilin University
OTHER
Renmin Hospital of Wuhan University
OTHER
First Affiliated Hospital of Chongqing Medical University
OTHER
Second Affiliated Hospital of Nanchang University
OTHER
Xijing Hospital
OTHER
The Affiliated Hospital of Qingdao University
OTHER
The Second Affiliated Hospital of Xinjiang Medical University
UNKNOWN
Shenzhen People's Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
The First People's Hospital of Yunnan
OTHER
The First Hospital of Jilin University
OTHER
Tianjin Huanhu Hospital
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
Wannan Medical College Yijishan Hospital
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
Beijing Tiantan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tiantan Hospital, Affiliated to Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HX-A-2024018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.